- Home
- Publications
- Publication Search
- Publication Details
Title
Regorafenib for Gastrointestinal Malignancies
Authors
Keywords
Imatinib, Sorafenib, Sunitinib, Nilotinib, Aflibercept
Journal
BIODRUGS
Volume 27, Issue 3, Pages 213-224
Publisher
Springer Nature
Online
2013-02-22
DOI
10.1007/s40259-013-0014-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRAF as a Target for Cancer Therapy
- (2012) Rodrigo Dienstmann et al. Anti-Cancer Agents in Medicinal Chemistry
- Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
- (2012) D Strumberg et al. BRITISH JOURNAL OF CANCER
- Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
- (2012) B. Sitohy et al. CANCER RESEARCH
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Regorafenib for cancer
- (2012) Dirk Strumberg et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Is there something other than imatinib mesilate in therapeutic options for GIST?
- (2012) Francesco Giuliani et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
- (2012) S. H. Park et al. INVESTIGATIONAL NEW DRUGS
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
- (2012) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- (2012) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Optimizing targeted cancer therapy: Towards clinical application of systems biology approaches
- (2011) Arend H. Sikkema et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp
- (2011) H. Prazeres et al. ENDOCRINE-RELATED CANCER
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Patent watch
- (2011) NATURE REVIEWS DRUG DISCOVERY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Multiple Kinase Pathways: A Change In Paradigm
- (2010) L. Gossage et al. CLINICAL CANCER RESEARCH
- Targeting RET Receptor Tyrosine Kinase Activation in Cancer
- (2010) J. E. Phay et al. CLINICAL CANCER RESEARCH
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer
- (2009) Hae-Young Yong et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now